collection
MENU ▼
Read by QxMD icon Read
search

LUNG

shared collection
378 papers 100 to 500 followers
https://www.readbyqxmd.com/read/29773328/molecular-and-immune-biomarker-testing-in-squamous-cell-lung-cancer-effect-of-current-and-future-therapies-and-technologies
#1
REVIEW
Fred R Hirsch, Keith M Kerr, Paul A Bunn, Edward S Kim, Coleman Obasaju, Maurice Pérol, Philip Bonomi, Jeffrey D Bradley, David Gandara, James R Jett, Corey J Langer, Ronald B Natale, Silvia Novello, Luis Paz-Ares, Suresh S Ramalingam, Martin Reck, Craig H Reynolds, Egbert F Smit, Mark A Socinski, David R Spigel, Thomas E Stinchcombe, Johan F Vansteenkiste, Heather Wakelee, Nick Thatcher
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC...
March 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29653950/personalised-medicine-in-interstitial-lung-diseases-number-6-in-the-series-personalised-medicine-in-respiratory-diseases-edited-by-renaud-louis-and-nicolas-roche
#2
Maria A Kokosi, George A Margaritopoulos, Athol U Wells
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised medicine a highly attractive concept. Personalised medicine is aimed at describing distinct disease subsets taking into account individual lifestyle, environmental exposures, genetic profiles and molecular pathways. The cornerstone of personalised medicine is the identification of biomarkers that can be used to inform diagnosis, prognosis and treatment stratification...
June 30, 2018: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29734788/yap-and-taz-in-lung-cancer-oncogenic-role-and-clinical-targeting
#3
REVIEW
Federica Lo Sardo, Sabrina Strano, Giovanni Blandino
Lung cancer is the leading cause of cancer death in the world and there is no current treatment able to efficiently treat the disease as the tumor is often diagnosed at an advanced stage. Moreover, cancer cells are often resistant or acquire resistance to the treatment. Further knowledge of the mechanisms driving lung tumorigenesis, aggressiveness, metastasization, and resistance to treatments could provide new tools for detecting the disease at an earlier stage and for a better response to therapy. In this scenario, Yes Associated Protein (YAP) and Trascriptional Coactivator with PDZ-binding motif (TAZ), the final effectors of the Hippo signaling transduction pathway, are emerging as promising therapeutic targets...
May 6, 2018: Cancers
https://www.readbyqxmd.com/read/29720509/state-of-the-art-in-interstitial-pneumonia-with-autoimmune-features-a-systematic-review-on-retrospective-studies-and-suggestions-for-further-advances
#4
REVIEW
Gianluca Sambataro, Domenico Sambataro, Sebastiano Emanuele Torrisi, Ada Vancheri, Mauro Pavone, Roberta Rosso, Matteo Schisano, Claudia Crimi, Francesca Pignataro, Aryeh Fischer, Nicoletta Del Papa, Carlo Vancheri
The term interstitial pneumonia with autoimmune features (IPAF) has been proposed to define patients with interstitial lung disease (ILD) associated with autoimmune signs not classifiable for connective tissue diseases (CTDs). This new definition overcomes previous nomenclatures and provides a uniform structure for prospective studies through specific classification criteria.This work evaluates the characteristics of IPAF patients reported in the literature, to highlight potential limits through a comparative analysis and to suggest better performing classification criteria...
June 30, 2018: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29675860/pulmonary-pleomorphic-carcinoma-a-case-harboring-egfr-mutation-treated-with-egfr-tkis
#5
Ken Masuda, Takaaki Tokito, Koichi Azuma, Eriko Yanagida, Masayuki Nakamura, Yoshiko Naito, Norikazu Matsuo, Hidenobu Ishii, Kazuhiko Yamada, Jun Akiba, Tomoaki Hoshino
Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanese woman was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21. Despite treatment with erlotinib, the patient died after two weeks as a result of rapid disease progression...
April 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29494219/molecular-diagnostics-in-pathology-time-for-a-next-generation-pathologist
#6
Matteo Fassan
CONTEXT: - Comprehensive molecular investigations of mainstream carcinogenic processes have led to the use of effective molecular targeted agents in most cases of solid tumors in clinical settings. OBJECTIVE: - To update readers regarding the evolving role of the pathologist in the therapeutic decision-making process and the introduction of next-generation technologies into pathology practice. DATA SOURCES: - Current literature on the topic, primarily sourced from the PubMed (National Center for Biotechnology Information, Bethesda, Maryland) database, were reviewed...
March 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29480761/eighth-edition-staging-of-thoracic-malignancies-implications-for-the-reporting-pathologist
#7
Andrew G Nicholson, Ming S Tsao, William D Travis, Deepa T Patil, Francoise Galateau-Salle, Mirella Marino, Sanja Dacic, Mary Beth Beasley, Kelly J Butnor, Yasushi Yatabe, Harvey I Pass, Valerie W Rusch, Frank C Detterbeck, Hisao Asamura, Thomas W Rice, Ramon Rami-Porta
Context The Staging and Prognostic Factors Committee of the International Association for the Study of Lung Cancer, in conjunction with the International Mesothelioma Interest Group, the International Thymic Malignancy Interest Group, and the Worldwide Esophageal Cancer Collaboration, developed proposals for the 8th edition of their respective tumor, node, metastasis (TNM) staging classification systems. Objective To review these changes and discuss issues for the reporting pathologist. Data Sources Proposals were based on international databases of lung (N = 94 708), with an external validation using the US National Cancer Database; mesothelioma (N = 3519); thymic epithelial tumors (10 808); and epithelial cancers of the esophagus and esophagogastric junction (N = 22 654)...
May 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29631763/iatrogenic-pulmonary-lesions
#8
REVIEW
Anja C Roden, Philippe Camus
Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eosinophilic pneumonia, pulmonary edema, diffuse alveolar damage, hypersensitivity pneumonitis, granulomatous interstitial lung disease, chronic bronchiolitis, and pulmonary hemorrhage...
March 23, 2018: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29577613/molecular-biological-analysis-in-a-patient-with-multiple-lung-adenocarcinomas
#9
Tomoshige Wakayama, Hirokuni Hirata, Shunsuke Suka, Kozo Sato, Masamitsu Tatewaki, Ryosuke Souma, Hideyuki Satoh, Motohiko Tamura, Yuji Matsumura, Hiroki Imada, Kumiya Sugiyama, Masafumi Arima, Kazuhiro Kurasawa, Takeshi Fukuda, Yasutsugu Fukushima
The utility of molecular biological analysis in lung adenocarcinoma has been demonstrated. Herein we report a rare case presenting as multiple lung adenocarcinomas with four different EGFR gene mutations detected in three lung tumors. After opacification was detected by routine chest X-ray, the patient, a 64-year-old woman, underwent chest computed tomography which revealed a right lung segment S4 ground-glass nodule (GGN). Follow-up computed tomography revealed a 42 mm GGN nodule with a 26 mm nodule (S6) and a 20 mm GGN (S10)...
March 26, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29606126/lymph-node-cancer-of-the-mediastinum-with-a-putative-necrotic-primary-lesion-in-the-lung-a-case-report
#10
Daichi Shikata, Takahiro Nakagomi, Rumi Higuchi, Yujiro Yokoyama, Toshio Oyama, Taichiro Goto
BACKGROUND: Although mediastinal lymph node cancer is presumed to originate in the lung, the primary site is usually unidentified, so the pathological course remains unclear. We recently encountered a case of mediastinal lymph node cancer having a putative primary lesion remaining in the lung as a necrotic focus. CASE PRESENTATION: The patient was a 56-year-old man who visited our department because computed tomography screening had revealed a nodular shadow in the lingular segment...
April 2, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29534030/any-place-for-immunohistochemistry-within-the-predictive-biomarkers-of-treatment-in-lung-cancer-patients
#11
REVIEW
Véronique Hofman, Sandra Lassalle, Coraline Bence, Elodie Long-Mira, Sacha Nahon-Estève, Simon Heeke, Virginie Lespinet-Fabre, Catherine Butori, Marius Ilié, Paul Hofman
The identification of certain genomic alterations ( EGFR , ALK , ROS1 , BRAF ) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned...
March 13, 2018: Cancers
https://www.readbyqxmd.com/read/29538329/update-on-immunohistochemistry-for-the-diagnosis-of-lung-cancer
#12
REVIEW
Kentaro Inamura
Immunohistochemistry is a widely available technique that is less challenging and can provide clinically meaningful results quickly and cost-efficiently in comparison with other techniques. In addition, immunohistochemistry allows for the evaluation of cellular localization of proteins in the context of tumor structure. In an era of precision medicine, pathologists are required to classify lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted therapies. This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma...
March 14, 2018: Cancers
https://www.readbyqxmd.com/read/29299424/dr-erik-thunnissen-how-to-appropriately-optimize-the-handling-of-surgically-resected-specimens
#13
Bella Poon, Chao-Xiu Melanie He
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29531901/next-generation-molecular-therapy-in-lung-cancer
#14
EDITORIAL
Jun Qian, Pierre P Massion
No abstract text is available yet for this article.
February 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29535908/small-cell-lung-cancer-updates-and-new-concepts
#15
Peter Ujhazy, O Wolf Lindwasser
No abstract text is available yet for this article.
February 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29535913/current-standards-for-clinical-management-of-small-cell-lung-cancer
#16
REVIEW
Anna F Farago, Florence K Keane
Small cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma. Despite over 30 years of clinical research, little progress has been made in the management of SCLC, and outcomes remain poor. Here, we review the current clinical standards for management of SCLC and the data supporting these strategies.
February 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29528556/role-of-circulating-tumor-dna-in-the-management-of-early-stage-lung-cancer
#17
REVIEW
Heng Zhao, Ke-Zhong Chen, Ben-Gang Hui, Kai Zhang, Fan Yang, Jun Wang
Lung cancer is one of the most common cancers and the predominant cause of cancer-related death in the world. The low accuracy of early detection techniques and high risk of relapse greatly contribute to poor prognosis. An accurate clinical tool that can assist in diagnosis and surveillance is urgently needed. Circulating tumor DNA (ctDNA) is free DNA shed from tumor cells and isolated from peripheral blood. The genomic profiles of ctDNA have been shown to closely match those of the corresponding tumors. With the development of approaches with high sensitivity and specificity, ctDNA plays a vital role in the management of lung cancer as a result of its reproducible, non-invasive, and easy-to-obtain characteristics...
May 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29491037/unclassifiable-interstitial-lung-disease-a-pathologist-s-perspective
#18
REVIEW
Kirk D Jones
Classifying pulmonary fibrotic disease into various diagnostic categories provides the clinician with expectations for both prognosis and proper treatment. Despite years of experience with histological, radiological and clinical guidelines, a group of patients remains with unclassifiable interstitial lung disease. In this article, the possible barriers to classification will be explored, and some strategies will be discussed to aid in overcoming these barriers.
March 31, 2018: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29455666/kras-oncogene-in-non-small-cell-lung-cancer-clinical-perspectives-on-the-treatment-of-an-old-target
#19
REVIEW
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset. However, in the last decade, multiple oncogenic driver alterations have been discovered and each of them represents a potential therapeutic target. Although KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed...
February 19, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29455669/egfr-tkis-resistance-via-egfr-independent-signaling-pathways
#20
REVIEW
Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu, Kongming Wu
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment. Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations. In an EGFR-dependent manner, acquired mutations, such as T790 M, interferes the interaction between TKIs and the kinase domain of EGFR...
February 19, 2018: Molecular Cancer
label_collection
label_collection
6334
1
2
2018-03-11 12:43:14
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"